title: Designing CAR T cells for glioblastoma.
abstract: Chimeric antigen receptor (CAR)-modified T cells directed against CD19 can mediate long-term durable remissions in B cell malignancies, but bringing a new target antigen to the clinic requires extensive modeling to avoid on-target and off-target toxicity. We recently described a systematic approach to test a new CAR directed against EGFR variant III.
authors.affiliation: Division of Hematology/Oncology, Department of Medicine; Perelman School of Medicine; University of Pennsylvania ; Abramson Cancer Center , Philadelphia, PA, USA.
authors.forename: Marcela V
authors.initials: MV
authors.lastname: Maus
keywords: CAR T cells, glioblastoma, EGFRvIII, adoptive cell therapy